Alps Group Inc (ALPS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alps Group Inc (ALPS) Healthcare & Pipeline Overview

Alps Group Inc, an integrated biotechnology platform, focuses on research and development, medical services, and wellness solutions within the advanced therapies sector. Headquartered in Kuala Lumpur, the company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.

What Is the Investment Thesis for ALPS?

Alps Group Inc presents a unique investment opportunity within the biotechnology sector, focusing on advanced therapies and integrated healthcare solutions. With a market capitalization of $66.6M, the company operates with a high-risk, high-reward profile, indicated by a negative profit margin of -2004.5%. Key value drivers include the potential for innovative breakthroughs in its research and development activities and the expansion of its medical services and wellness solutions. Growth catalysts include strategic partnerships, successful clinical trials, and regulatory approvals for its advanced therapies. However, investors should be aware of potential risks, including the company's negative profitability, reliance on research outcomes, and competition within the biotechnology industry. The company's beta of 0.25 suggests lower volatility compared to the market, but the absence of a dividend yield reflects its focus on reinvesting earnings for growth.

Based on FMP financials and quantitative analysis

ALPS Key Highlights

Market capitalization of $66.6M indicates the company's current valuation in the biotechnology market.

• Gross margin of 38.6% reflects the company's efficiency in converting revenue into profit after accounting for the cost of goods sold.
• Profit margin of -2004.5% highlights significant losses relative to revenue, indicating potential challenges in achieving profitability.
• Beta of 0.25 suggests lower volatility compared to the overall market, potentially offering a more stable investment.
• Focus on advanced therapies positions the company in a high-growth area within the biotechnology sector.

Who Are ALPS's Competitors?

ALPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALPS's Key Strengths?

Integrated biotechnology platform.

• Focus on advanced therapies.
• Commitment to accessible healthcare.
• Research and development capabilities.

What Are ALPS's Weaknesses?

Negative profit margin.

• Small employee base.
• Limited market presence.
• Reliance on research outcomes.

What Could Drive ALPS Stock Higher?

Clinical trial results for advanced therapies may drive investor interest and stock appreciation.

• Regulatory approvals for new medical devices or treatments can expand market access and revenue potential.
• Strategic partnerships with pharmaceutical companies or research institutions can accelerate product development and commercialization.

What Are the Key Risks for ALPS?

Listing risk — at $0.40 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -30.73 sits in the distress zone (elevated bankruptcy risk).
• Negative profit margin may hinder the company's ability to fund research and development activities.
• Competition from larger biotechnology companies with greater resources may limit market share and growth opportunities.
• Regulatory changes and compliance requirements in the healthcare industry may increase operating costs and delay product approvals.

What Are the Growth Opportunities for ALPS?

• Expansion into New Therapeutic Areas: Alps Group Inc has the opportunity to expand its research and development efforts into new therapeutic areas, such as oncology, neurology, and infectious diseases. By diversifying its research portfolio, Alps Group Inc can reduce its reliance on specific therapeutic areas and capitalize on emerging market opportunities, potentially leading to significant revenue growth and increased market share.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and technology providers can accelerate Alps Group Inc's research and development efforts and expand its market reach. Collaborations can provide access to new technologies, funding, and expertise, enabling the company to develop and commercialize its advanced therapies more efficiently. These partnerships can also enhance Alps Group Inc's credibility and attract further investment, driving long-term growth and innovation.
• Geographic Expansion into Emerging Markets: Expanding its operations into emerging markets, particularly in Asia and Latin America, can provide Alps Group Inc with access to new customer segments and revenue streams. These markets often have unmet healthcare needs and a growing demand for advanced therapies and wellness solutions. By establishing a presence in these regions, Alps Group Inc can capitalize on the increasing healthcare spending and improve its global market position, driving sustainable growth and profitability.
• Development of Personalized Medicine Solutions: Investing in the development of personalized medicine solutions, such as diagnostic tests and targeted therapies, can differentiate Alps Group Inc from its competitors and attract a growing segment of healthcare consumers. Personalized medicine leverages an individual's genetic information to tailor treatments and improve outcomes. As the cost of genetic sequencing decreases and the understanding of genomics increases, the demand for personalized medicine solutions is expected to grow significantly, creating a substantial market opportunity for Alps Group Inc.
• Integration of Digital Health Technologies: Incorporating digital health technologies, such as telehealth platforms, wearable devices, and mobile health apps, can enhance Alps Group Inc's service offerings and improve patient engagement. Digital health technologies can facilitate remote monitoring, personalized coaching, and data-driven insights, leading to better health outcomes and increased customer satisfaction. By integrating these technologies into its healthcare ecosystem, Alps Group Inc can create a more comprehensive and accessible suite of services, driving customer loyalty and revenue growth.

What Threats Does ALPS Face?

• Competition from established biotechnology companies.
• Regulatory hurdles and compliance requirements.
• Economic downturns affecting healthcare spending.
• Patent expirations and intellectual property risks.

What Are ALPS's Competitive Advantages?

• Integrated biotechnology platform combining research, medical services, and wellness solutions.
• Focus on advanced therapies and personalized medicine.
• Commitment to creating a fair and accessible healthcare ecosystem.

What Does ALPS Do?

Alps Group Inc, based in Kuala Lumpur, Malaysia, is an integrated biotechnology platform dedicated to advancing healthcare through research and development, medical services, and wellness solutions. The company focuses on advanced therapies, aiming to create a healthcare ecosystem that emphasizes predictive, preventive, and precision medicine. Alps Group Inc operates with a vision of making healthcare more accessible and equitable. The company's activities span across several key areas, including biotechnology research, medical service delivery, and the development of wellness solutions. These activities are all geared towards providing advanced therapies that address a range of medical needs. Alps Group Inc aims to be at the forefront of medical innovation, contributing to the development of new treatments and healthcare strategies. The company's integrated approach allows it to combine research insights with practical medical applications, enhancing the effectiveness and accessibility of its offerings. Alps Group Inc is committed to improving patient outcomes and promoting overall well-being through its diverse range of healthcare solutions.

What Products and Services Does ALPS Offer?

• Conducts research and development in advanced therapies.
• Provides medical services focused on predictive, preventive, and precision medicine.
• Develops and offers wellness solutions.
• Aims to create a fair and accessible healthcare ecosystem.
• Integrates biotechnology with medical service delivery.
• Focuses on improving patient outcomes through innovative treatments.

How Does ALPS Make Money?

• Generates revenue through research and development activities.
• Provides medical services and wellness solutions to patients.
• Aims to commercialize advanced therapies and healthcare technologies.

What Industry Does ALPS Operate In?

Alps Group Inc operates within the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The global biotechnology market is projected to reach significant growth in the coming years, driven by advancements in genomics, personalized medicine, and biopharmaceuticals. Companies in this sector face intense competition from both established pharmaceutical giants and emerging biotech firms. Alps Group Inc's focus on integrated healthcare solutions and advanced therapies positions it to capitalize on the growing demand for innovative medical treatments and wellness programs.

Who Are ALPS's Key Customers?

• Patients seeking advanced medical treatments.
• Individuals interested in wellness solutions.
• Healthcare providers and institutions.
• Research partners and collaborators.

Alps Group Inc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -30.73 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.

Alps Group Inc (ALPS) Valuation Context

Valued at $66.6M, ALPS is classified as a micro-cap stock. Relative to its peer group, ALPS's quantitative score of 19/100 is below the peer average of 77/100.

ALPS Revenue & Earnings Trend

In Sep 2025, ALPS generated $0 in top-line revenue. The company recorded a net loss of $828K, with diluted EPS of $-0.24. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ALPS averaged $-3.69 in diluted EPS.

Company Profile

Alps Group Inc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kuala Lumpur, MY. The company is led by CEO Seng Kong Tham. ALPS has traded publicly since 2025.

ALPS Financials

ALPS Latest News

ALPS Analyst Consensus

ALPS MoonshotScore

Common Questions About ALPS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources